Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Shusuke Yagi; Yukina Hirata; Takayuki Ise; Kenya Kusunose; Hirotsugu Yamada; Daiju Fukuda; Hotimah Masdan Salim; Gulinu Maimaituxun; Susumu Nishio; Yuriko Takagawa; Saori Hama; Tomomi Matsuura; Koji Yamaguchi; Takeshi Tobiume; Takeshi Soeki; Tetsuzo Wakatsuki; Ken-ichi Aihara; Masashi Akaike; Michio Shimabukuro; Masataka Sata

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

2017

Abstract Background It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. Methods and results We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes. Conclusion Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).

Afficher plus [+]